Effects of rosuvastatin and atorvastatin on inflammatory factors in patients with acute coronary syndrome
10.3760/cma.j.issn.1008-6315.2009.04.014
- VernacularTitle:瑞舒伐他汀与不同剂量阿托伐他汀对急性冠状动脉综合征患者炎症因子的影响
- Author:
Ruina KONG
;
Luosha ZHAO
;
Yan CHEN
;
Jinghan WEI
;
Fan YANG
;
Yanhua YANG
;
Lin LIU
- Publication Type:Journal Article
- Keywords:
Acute coronary syndrome;
Rosuvastatin;
Atorvastatin;
Matrix metalloproteinases-9;
Plasminogen activator inhibitor-1
- From:Clinical Medicine of China
2009;25(4):372-374
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of 10 mg and 20 mg atorvastatin and 10 mg rosuvastatin on inflammatory factors in patients with acute coronary syndrome (ACS).Methods 66 patients with ACS were randomly divided into three groups:the 10 mg atorvastatin group,the 20 mg atorvastatin group and the 10 mg rosuvastatin group(n=22 for each group).The levels of blood lipids,serum matrix metalloproteinases-9 (MMP-9)and plasminogen activator inhibitor-1 (PAI-1)were measured before and after two-week treatment.19 patients with normal coronary angiography were assigned to the control group.Results The concentration of serum MMP-9 and PAI-1 was higher significantly in patients with ACS than those in control subjects(P＜0.05 or P＜0.01).After two weeks'treatment,the serum MMP-9 and PAI-1 levels were lowered significantly (P＜0.01),which were much better in groups of 20mg atorvastatin and of 10mg rosuvastatin than those in group of 10mg atorvastatin (P＜0.05 or P＜0.01 ).No relationship was observed between the levels of above inflammatory markers and serum hpids levels(P＞0.05).Conclusion 10 mg Rosuvastatin can greatly reduce the serum level of MMP-9 and PAI-1 as compared to 10 mg atorvastatin in patients with ACS ,equivalent to the effect of 20 mg atorvastatin,suggesting that the anti-inflammatory effect is independent of lipid-lowering action.
